Antibodies for Targeted Imaging: Properties and Radiolabeling

Author(s):  
Noboru Oriuchi ◽  
David J. Yang
1984 ◽  
Vol 45 (C2) ◽  
pp. C2-93-C2-96
Author(s):  
M. J. Simpson ◽  
M. T. Browne ◽  
R. E. Burge ◽  
P. Charalambous ◽  
P. J. Duke ◽  
...  

1997 ◽  
Vol 38 (5) ◽  
pp. 665-676 ◽  
Author(s):  
Chen Wang ◽  
P. B. Gordon ◽  
S. O. Hustvedt ◽  
D. Grant ◽  
A. Tufte Sterud ◽  
...  

2020 ◽  
Vol 27 (41) ◽  
pp. 6968-6986
Author(s):  
Rui Cao ◽  
Hongguang Liu ◽  
Zhen Cheng

Liver cancer/Hepatocellular Carcinoma (HCC) is a leading cause of cancer death and represents an important cause of mortality worldwide. Several biomarkers are overexpressed in liver cancer, such as Glypican 3 (GPC3) and Epidermal Growth Factor Receptor (EGFR). These biomarkers play important roles in the progression of tumors and could serve as imaging and therapeutic targets for this disease. Peptides with adequate stability, receptor binding properties, and biokinetic behavior have been intensively studied for liver cancer imaging. A great variety of them have been radiolabeled with clinically relevant radionuclides for liver cancer diagnosis, and many are promising imaging and therapeutic candidates for clinical translation. Herein, we summarize the advancement of radiolabeled peptides for the targeted imaging of liver cancer.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Lynne L. Johnson ◽  
Jordan Johnson ◽  
Ziad Ali ◽  
Yared Tekabe ◽  
Rebecca Ober ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document